Shareholders' equity · 2018–2025

Keros Therapeutics shareholders' equity

$303M−47.0% · FY2025

Keros Therapeutics (KROS) reported $303M in shareholders' equity for fiscal 2025, −47.0% year on year.

−$7.2M2018−$19.4M2019$262M2020$243M2021$277M2022$332M2023$572M2024$303M2025
Keros Therapeutics — Shareholders' equity, 2018–2025
Fiscal yearShareholders' equityChangeFiling
FY20252025-12-31$303M−47.0%Open →
FY20242024-12-31$572M+72.0%Open →
FY20232023-12-31$332M+19.7%Open →
FY20222022-12-31$277M+14.1%Open →
FY20212021-12-31$243M−7.1%Open →
FY20202020-12-31$262M+$281MOpen →
FY20192019-12-31−$19.4M−$12.3MOpen →
FY20182018-12-31−$7.2M—Open →

Shareholders' equity — Shareholders' equity is what remains after subtracting liabilities from assets — the accounting book value of the company, not its market value.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026

Shareholders' equity at companies of similar size

Full ranking by shareholders' equity →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Keros Therapeutics shareholders' equity |url=https://companiesranked.com/en/company/keros-therapeutics/shareholders-equity |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Keros Therapeutics shareholders' equity. CompaniesRanked. https://companiesranked.com/en/company/keros-therapeutics/shareholders-equity

BibTeX

@misc{companiesranked-en-company-keros-therapeutics-shareholders-equity-2026,
  author       = {{CompaniesRanked}},
  title        = {{Keros Therapeutics shareholders' equity}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/keros-therapeutics/shareholders-equity}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-Q · 0001664710-26-000049 · August 3, 2026

{{cite web |title=Keros Therapeutics shareholders' equity — 10-Q (0001664710-26-000049) |url=https://www.sec.gov/Archives/edgar/data/1664710/000166471026000049/kros-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-03}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Keros Therapeutics overview